vaccine protector
A technology of vaccine protective agent and protective agent, which is applied in antiviral agents, antibody medical components, viruses/bacteriophages, etc. It can solve the problems of high cost of trehalose and increased vaccine costs, and achieve the effect of simple components
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0027] Embodiment 1 Serum-free human rabies vaccine protective agent of the present invention
[0028] The formula of the vaccine protection agent is: 2.5 parts by weight of sucrose, 2.5 parts by weight of maltose, 0.3 parts by weight of urea, and 3 parts by weight of human albumin.
[0029] When in use, the vaccine protective agent is dissolved in a phosphate buffer solution with a NaCl content of 0.2% to 0.9% (m / v), and the purified inactivated virus solution is added to make the final concentration of sucrose in the mixture 2.5% (m / v). v), the final concentration of maltose is 2.5% (m / v), the final concentration of urea is 0.3% (m / v), and the final concentration of human serum albumin is 3% (m / v).
Embodiment 2
[0030] Embodiment 2 Serum-free human rabies vaccine protective agent of the present invention
[0031] The formula of the vaccine protection agent is: 5 parts by weight of sucrose, 5 parts by weight of maltose, 0.5 part by weight of urea, and 1 part by weight of human albumin, which are dissolved in phosphate buffer saline with a NaCl content of 0.2% (m / v).
[0032] When in use, the vaccine protective agent is dissolved in a phosphate buffer solution with a NaCl content of 0.2% to 0.9% (m / v), and the purified inactivated virus solution is added to make the final concentration of sucrose in the mixture 5% (m / v). v), the final concentration of maltose is 5% (m / v), the final concentration of urea is 0.5% (m / v), and the final concentration of human serum albumin is 1% (m / v).
[0033] The present invention will be further described in the form of experimental examples below.
experiment example 1
[0034] Effect comparison of experimental example 1 rabies vaccine protective agent
[0035] 1. Preparation of inactivated virus solution
[0036] 1. Production cells
[0037] The cells used for production are Vero cells cultured without serum (serum-free Vero cells for short), which are imported from ATCC in the United States.
[0038] 2. Poison species
[0039] The virus used for production is the fixed rabies virus rPV-2061 strain, which was introduced from the CDC of the United States.
[0040] 3. Stock solution preparation
[0041] (1) Cell culture: Serum-free Vero cells were cultured at 37°C after recovery, and were continuously passaged and expanded at a split ratio of 1:3. After expansion, the cells were made into cell suspension, according to 6×10 5 The density of cells / ml was inoculated into a fixed-bed bioreactor (referred to as "bioreactor", the same below), and serum-free culture medium was used for perfusion culture. Culture parameters: temperature=37.0° C.,...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More